16476 results for "sec+and+unspecified+malignant+neoplasm"

in 19.75 milliseconds.

• Human T-bet governs innate and innate-like adaptive IFN-g immunity against mycobacteria

  Dac EGAC00001001822

• Data Access Committee for the project: Epic arrays from human OB and their mimics

  Dac EGAC00001002482

• EGAD00000000029

  Aggregate results from a case-control study on stroke and ischemic stroke.

  Dataset EGAD00000000029

• PDX-OmniExpress24

  Primary and PDX SqCC samples using Infinium OmniExpress-24

  Dataset EGAD00010001228

• PTPN22 LOTx dataset

  Genotype of PTPN22 SNPs in LOTx donors and recipients

  Dataset EGAD00010001645

• PELICAN45 and GP21 prostate cancer studies Data Access Committee

  Dac EGAC00001001309

• Stability of gut microbiome after COVID-19 vaccination in healthy and immuno-compromised individuals

  Dac EGAC50000000123

• Cyr61-MAC DAC

  DAC for access to dataset on Cyr61-MAC and HUVEC

  Dac EGAC50000000355

• Epigenome-wide association study of asthma remission in whole blood and nasal epithelium

  Study EGAS00001004766

• Detailed molecular and immune marker profiling of archival prostate cancer samples

  Study EGAS00001004396

• Dataset with genome-wide array data from 64 Tunisian and 45 Moroccan individuals.

  Study EGAS00001006427

• WGS of KCNQ2 R201C patient derived iPSC and its isogenic line

  Study EGAS00001007231

• Single-cell sequencing of adipose-derived mesenchymal stromal cells and dermal fibroblasts

  Study EGAS00001006954

• Follicular Lymphoma Whole Genome and Transcriptome Sequencing

  Study EGAS00001006646

• Integrative pan-cancer genomic and transcriptomic analyses of refractory metastatic cancer

  Study EGAS00001006648

• Platelets sequester extracellular DNA, capturing tumour-derived and free fetal DNA

  Study EGAS00001006854

• scATAC-seq and combined scRNA-seq of the human first trimester neurodevelopment

  Study EGAS00001007472

• Methylation clocks - individual colon, small intestine and endometrial crypts

  Study EGAS00001005514

• Volkov Data Access Committee

  Sequencing and analysis data supporting published work of Hadas Volkov

  Dac EGAC50000000907

• Sensitive and reproducible cell-free methylome quantification with synthetic spike-in controls

  Study EGAS00001005069

• Clonal Driver Neoantigen Loss under EGFR TKI and Immune Selection Pressures

  NNN

  Study EGAS00001007926

• Genome-wide methylation detection and episignature analysis using PacBio long-read sequencing

  Study EGAS00001008250

• 20200819_EGA_Qld_Melanoma.radiomics

  A radiomics study integrating PET/CT, WES and RNAseq data

  Dataset EGAD00001006375

• Localised colon cancer WES study contaning WBCs, tissue and plasma samples at different time points

  Decision-making based on circulating tumor DNA (ctDNA) status following curative-intent surgery in stage II-III colon cancer (CC) is where the strongest clinical evidence lies. Commercial or academic assays are predominantly used to detect ctDNA, aiming to reveal minimal residual disease (MRD) and identify patients at high risk of recurrence. However, while current tests demonstrate exceptional specificity in detecting MRD among patients who later experience recurrence, their sensitivity is notably limited, particularly immediately after surgery when decisions regarding ACT are crucial. Additionally, up to 70% of patients with stage II-III colon cancer fail to clear ctDNA after standard adjuvant treatment (ACT) and subsequently experience recurrence. In this study, we performed whole exome sequencing (WES) of ctDNA at different timepoints in relapsed CC patients using two independent cohorts, alongside transcriptomic and proteomic analyses of metastases to gain a deeper understanding of progression mechanisms. An assay based on a tumor-agnostic approach from WES could enhance sensitivity in detecting MRD disease compared to current assays. Immune evasion appears to be the primary driver of progression in the localized CC setting, facilitated by a functional mutational burden at relapse. This suggests that immunotherapy could extend its efficacy to patients with microsatellite stability, broadening treatment options. Moreover, organoid modeling affirms the promising potential of targeted therapy to surpass conventional treatments in eradicating MRD.

  Study EGAS50000000204

• Cell fate mapping of human glioblastoma reveals an invariant stem cell hierarchy pre- and post-treatment

  Human glioblastomas (GBMs) are thought to harbour a subpopulation of glioblastoma stem cells (GSCs) that initiate tumour formation and regrowth following treatment. However, the origin of their proliferative heterogeneity during tumour growth pre- and post-treatment remains poorly understood. Here we study the clonal evolution of DNA barcoded GBMs following their serial propagation in xenograft mouse models to define the fate behaviour of individual GBM cells. Through quantitative analysis of clone sizes scored across multiple passages, we show that the growth of GBM clones in vivo are consistent with a remarkably neutral process resulting from a conserved proliferative hierarchy. In this model, slow-cycling stem-like cells give rise to a more rapidly cycling progenitor population with extensive self-maintenance capacity, that in turn generates short-lived cells that lack proliferative ability. We also identify rare "outlier" clones that deviate from these dynamics, and further show that chemotherapy reproducibly facilitates the selective expansion of pre-existing drug-resistant GBM lineages. Finally, we show that coexisting, functionally distinct GSCs may be targeted separately with epigenetic compounds. These findings show that, independent of an evolving mutational signature, the clonal dynamics of human GBM can be surprisingly robust, with intratumoural heterogeneity derived primarily from the defined stochastic fate behaviour of tumour cells within a conserved proliferative hierarchy.

  Study EGAS00001002424